Log in

NASDAQ:OTLKOutlook Therapeutics News Headlines

$1.02
+0.01 (+0.99 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.93
Now: $1.02
$1.03
50-Day Range
$0.59
MA: $0.72
$1.05
52-Week Range
$0.50
Now: $1.02
$2.95
Volume1.48 million shs
Average Volume857,228 shs
Market Capitalization$93.21 million
P/E RatioN/A
Dividend YieldN/A
Beta0.09

Headlines

Outlook Therapeutics (NASDAQ OTLK) News Headlines

Source:
DateHeadline
HC Wainwright Reiterates "Buy" Rating for Outlook Therapeutics (NASDAQ:OTLK)HC Wainwright Reiterates "Buy" Rating for Outlook Therapeutics (NASDAQ:OTLK)
www.americanbankingnews.com - May 27 at 9:45 AM
Outlook Therapeutics announces $16M private placement to advance development of ONS-5010Outlook Therapeutics announces $16M private placement to advance development of ONS-5010
seekingalpha.com - May 26 at 6:35 PM
Outlook Therapeutics Announces $16.0 Million Private Placement to Advance the Development of ONS-5010 / LYTENAVA™ (bevacizumab-vikg)Outlook Therapeutics Announces $16.0 Million Private Placement to Advance the Development of ONS-5010 / LYTENAVA™ (bevacizumab-vikg)
finance.yahoo.com - May 26 at 8:34 AM
FY2024 EPS Estimates for Outlook Therapeutics, Inc. Lifted by Oppenheimer (NASDAQ:OTLK)FY2024 EPS Estimates for Outlook Therapeutics, Inc. Lifted by Oppenheimer (NASDAQ:OTLK)
www.americanbankingnews.com - May 21 at 11:57 AM
Some Analysts Just Cut Their Outlook Therapeutics, Inc. (NASDAQ:OTLK) EstimatesSome Analysts Just Cut Their Outlook Therapeutics, Inc. (NASDAQ:OTLK) Estimates
finance.yahoo.com - May 20 at 10:51 AM
Outlook Therapeutics (OTLK) "Buy" Rating Reiterated at HC WainwrightOutlook Therapeutics' (OTLK) "Buy" Rating Reiterated at HC Wainwright
www.americanbankingnews.com - May 19 at 6:38 AM
Outlook Therapeutics (OTLK) Buy Rating Reaffirmed at OppenheimerOutlook Therapeutics' (OTLK) Buy Rating Reaffirmed at Oppenheimer
www.americanbankingnews.com - May 18 at 10:24 AM
Outlook Therapeutics EPS misses by $0.01Outlook Therapeutics EPS misses by $0.01
seekingalpha.com - May 15 at 8:23 AM
Outlook Therapeutics Reports Financial Results for the Second Quarter of Fiscal Year 2020 and Provides Corporate UpdateOutlook Therapeutics Reports Financial Results for the Second Quarter of Fiscal Year 2020 and Provides Corporate Update
finance.yahoo.com - May 15 at 8:23 AM
Global Parkinsons Disease Therapeutics Market (COVID-19 Impact Analysis) - Latest Industry Research and Future Growth OutlookGlobal Parkinson's Disease Therapeutics Market (COVID-19 Impact Analysis) - Latest Industry Research and Future Growth Outlook
www.marketwatch.com - May 12 at 2:42 AM
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Given Consensus Rating of "Buy" by BrokeragesOutlook Therapeutics, Inc. (NASDAQ:OTLK) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 10 at 5:01 AM
Outlook Therapeutics (NASDAQ:OTLK) Research Coverage Started at Brookline Capital ManagementOutlook Therapeutics (NASDAQ:OTLK) Research Coverage Started at Brookline Capital Management
www.americanbankingnews.com - May 5 at 12:22 PM
BRIEF-Outlook Therapeutics Inc - Board Increased Size Of Board From Five To Seven MembersBRIEF-Outlook Therapeutics Inc - Board Increased Size Of Board From Five To Seven Members
www.reuters.com - April 21 at 9:48 PM
Outlook Therapeutics to Present at the April 2020 Virtual Investor SummitOutlook Therapeutics to Present at the April 2020 Virtual Investor Summit
www.benzinga.com - April 15 at 9:11 AM
Premature Ejaculation Therapeutics Market Outlook, 2020-2025 - High Demand for Topical Drug Therapies for PE Treatment - ResearchAndMarkets.comPremature Ejaculation Therapeutics Market Outlook, 2020-2025 - High Demand for Topical Drug Therapies for PE Treatment - ResearchAndMarkets.com
www.businesswire.com - April 14 at 6:53 PM
Outlook Therapeutics provides clinical updates amid COVID-19Outlook Therapeutics provides clinical updates amid COVID-19
seekingalpha.com - April 14 at 1:53 PM
Outlook Therapeutics Provides COVID-19 Impact Update on Ongoing Clinical Trials NORSE 1 and NORSE 2Outlook Therapeutics Provides COVID-19 Impact Update on Ongoing Clinical Trials NORSE 1 and NORSE 2
finance.yahoo.com - April 14 at 8:53 AM
Anemia Therapeutics Market Growth and Technology Advancement Outlook 2020 to 2029Anemia Therapeutics Market Growth and Technology Advancement Outlook 2020 to 2029
www.marketwatch.com - April 13 at 7:50 AM
Investors Who Bought Outlook Therapeutics (NASDAQ:OTLK) Shares Three Years Ago Are Now Down 98%Investors Who Bought Outlook Therapeutics (NASDAQ:OTLK) Shares Three Years Ago Are Now Down 98%
finance.yahoo.com - March 19 at 3:12 PM
Outlook Therapeutics Announces LYTENAVA™ (bevacizumab-vikg), Anticipated Brand Name for ONS-5010, If ApprovedOutlook Therapeutics Announces LYTENAVA™ (bevacizumab-vikg), Anticipated Brand Name for ONS-5010, If Approved
finance.yahoo.com - March 5 at 8:27 AM
Outlook Therapeutics, Inc. Common Stock (OTLK) SEC FilingsOutlook Therapeutics, Inc. Common Stock (OTLK) SEC Filings
www.nasdaq.com - March 2 at 10:23 PM
Outlook Therapeutics Announces Closing of $10.2 Million Financings Priced At-The-MarketOutlook Therapeutics Announces Closing of $10.2 Million Financings Priced At-The-Market
finance.yahoo.com - February 26 at 2:46 PM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Outlook Therapeutics, Inc.-OTLKSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Outlook Therapeutics, Inc.-OTLK
finance.yahoo.com - February 25 at 1:30 PM
BRIEF-Sabby Management LLC Reports 5.56% Passive Stake In Outlook TherapeuticsBRIEF-Sabby Management LLC Reports 5.56% Passive Stake In Outlook Therapeutics
www.reuters.com - February 24 at 6:11 PM
Outlook Therapeutics Announces $10.2 Million Financings Priced At-The-MarketOutlook Therapeutics Announces $10.2 Million Financings Priced At-The-Market
finance.yahoo.com - February 24 at 8:10 AM
INVESTOR ALERT: Fields Kupka & Shukurov LLP Is Investigating Outlook Therapeutics, Inc. for Potential Securities Violations and Breach of Fiduciary Duty Claims.INVESTOR ALERT: Fields Kupka & Shukurov LLP Is Investigating Outlook Therapeutics, Inc. for Potential Securities Violations and Breach of Fiduciary Duty Claims.
finance.yahoo.com - February 18 at 5:08 PM
Outlook Therapeutics Provides Business Update and Reports Financial Results for the First Quarter of Fiscal Year 2020Outlook Therapeutics Provides Business Update and Reports Financial Results for the First Quarter of Fiscal Year 2020
finance.yahoo.com - February 14 at 12:27 PM
Outlook Therapeutics to Present at the 2020 BIO CEO & Investor ConferenceOutlook Therapeutics to Present at the 2020 BIO CEO & Investor Conference
finance.yahoo.com - February 4 at 8:28 AM
Outlook Therapeutics streamlines capital structure; shares down 6% premarketOutlook Therapeutics streamlines capital structure; shares down 6% premarket
seekingalpha.com - January 28 at 1:43 PM
BRIEF-Outlook Therapeutics To Regain 100% Ownership Of Any Future Net Profits For Ons-5010BRIEF-Outlook Therapeutics To Regain 100% Ownership Of Any Future Net Profits For Ons-5010
www.msn.com - January 28 at 8:42 AM
Outlook Therapeutics Announces Agreements to Streamline Capital Structure and Regain 100% Ownership of Any Future Net Profits for ONS-5010Outlook Therapeutics Announces Agreements to Streamline Capital Structure and Regain 100% Ownership of Any Future Net Profits for ONS-5010
finance.yahoo.com - January 28 at 8:42 AM
Global Industrial Salts Market Outlook (2018-2027) - Market Set to Reach $19.90 billion by 2027 - ResearchAndMarkets.comGlobal Industrial Salts Market Outlook (2018-2027) - Market Set to Reach $19.90 billion by 2027 - ResearchAndMarkets.com
www.benzinga.com - January 18 at 12:53 PM
Supply Chain Analytics Market Analysis, Strategic Assessment, Trend Outlook and Bussiness Opportunities 2020-2023Supply Chain Analytics Market Analysis, Strategic Assessment, Trend Outlook and Bussiness Opportunities 2020-2023
www.marketwatch.com - January 18 at 12:53 PM
Eco Outlook epilogue: Presenters answer audience questions texted in real-timeEco Outlook epilogue: Presenters answer audience questions texted in real-time
www.bizjournals.com - January 18 at 12:53 PM
Philly Fed Outlook shoots higher in JanuaryPhilly Fed Outlook shoots higher in January
seekingalpha.com - January 18 at 12:53 PM
BRIEF-Outlook Therapeutics Announces Completion Of Warrant RestructuringBRIEF-Outlook Therapeutics Announces Completion Of Warrant Restructuring
www.msn.com - December 26 at 9:12 AM
Outlook completes warrant restructuringOutlook completes warrant restructuring
seekingalpha.com - December 26 at 9:12 AM
Outlook Therapeutics Announces Completion of Warrant RestructuringOutlook Therapeutics Announces Completion of Warrant Restructuring
finance.yahoo.com - December 26 at 9:12 AM
BRIEF-Outlook Therapeutics Announces Warrant Amendment And Restructuring Of Senior Secured Notes In Separate TransactionsBRIEF-Outlook Therapeutics Announces Warrant Amendment And Restructuring Of Senior Secured Notes In Separate Transactions
www.msn.com - December 23 at 11:07 PM
Outlook down 63% premarket on issuing warrant amendmentOutlook down 63% premarket on issuing warrant amendment
seekingalpha.com - December 23 at 1:06 PM
Outlook Therapeutics Announces Warrant Amendment and Restructuring of Senior Secured Notes in Separate TransactionsOutlook Therapeutics Announces Warrant Amendment and Restructuring of Senior Secured Notes in Separate Transactions
finance.yahoo.com - December 23 at 1:06 PM
Outlook Therapeutics Provides Business Update and Reports Financial Results for Fiscal Year 2019Outlook Therapeutics Provides Business Update and Reports Financial Results for Fiscal Year 2019
finance.yahoo.com - December 19 at 8:58 AM
BRIEF-Outlook Therapeutics Receives FDA Agreement For Three Special Protocol Assessments For Additional Planned Clinical Trials Of ONS-5010BRIEF-Outlook Therapeutics Receives FDA Agreement For Three Special Protocol Assessments For Additional Planned Clinical Trials Of ONS-5010
www.msn.com - December 3 at 7:34 PM
Outlook Therapeutics up 49% on advancement of ONS-5010Outlook Therapeutics up 49% on advancement of ONS-5010
seekingalpha.com - December 3 at 7:34 PM
Outlook Therapeutics Receives FDA Agreement for Three Special Protocol Assessments for Additional Planned Clinical Trials of ONS-5010Outlook Therapeutics Receives FDA Agreement for Three Special Protocol Assessments for Additional Planned Clinical Trials of ONS-5010
finance.yahoo.com - December 3 at 9:33 AM
What Kind Of Shareholders Own Outlook Therapeutics, Inc. (NASDAQ:OTLK)?What Kind Of Shareholders Own Outlook Therapeutics, Inc. (NASDAQ:OTLK)?
finance.yahoo.com - November 13 at 12:12 PM
Outlook Therapeutics Signs Manufacturing Supply Agreement with FUJIFILM Diosynth Biotechnologies as Part of CommercializationOutlook Therapeutics Signs Manufacturing Supply Agreement with FUJIFILM Diosynth Biotechnologies as Part of Commercialization
www.bloomberg.com - November 9 at 11:15 PM
Outlook Therapeutics to Present at the 29th Annual Ladenburg Thalmann 2019 Healthcare ConferenceOutlook Therapeutics to Present at the 29th Annual Ladenburg Thalmann 2019 Healthcare Conference
finance.yahoo.com - September 11 at 12:29 PM
Outlook Therapeutics (OTLK) Presents At H.C. Wainwright 21st Annual Global Investment Conference - SlideshowOutlook Therapeutics (OTLK) Presents At H.C. Wainwright 21st Annual Global Investment Conference - Slideshow
seekingalpha.com - September 10 at 3:47 PM
Outlook Therapeutics to Present at the H.C. Wainwright 21st Annual Healthcare ConferenceOutlook Therapeutics to Present at the H.C. Wainwright 21st Annual Healthcare Conference
finance.yahoo.com - September 10 at 3:47 PM
This page was last updated on 5/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.